Triple Bio Raises $1.7M Seed Round to Develop Lipid-Based Feed Additive Platform for Dairy Cows
Netherlands‑based startup Triple Bio emerged from stealth and raised just over €1.5 million ($1.7 million) from investors Nucleus Capital, Positron Ventures and Climate Club. The funding will support development of its lipid‑based feed additive platform RumeNRG, which aims to boost milk yields and cut methane emissions from cattle. The round marks the company’s first external capital after being founded by Marble’s climate‑tech studio.
Degron Secures $40M Series A Funding to Advance Molecular Glue Degraders
Degron, a biotech company focused on molecular glue degraders, announced the closing of a $40 million Series A financing round. The funding will be used to accelerate development of its molecular glue degrader platform.
Parabilis Medicines Announces Plans for IPO
Parabilis Medicines, the biotech spin‑out from Greg Verdine’s Harvard lab, announced its intention to go public, aiming to become the 12th drug developer to list on the exchange. The announcement follows a Regeneron deal the day before, underscoring rising biotech...
Neurosoft Bioelectronics Secures $7.5M Seed Funding Led by Skybound Venture Capital
Swiss neurotechnology firm Neurosoft Bioelectronics raised $7.5 million in a seed round led by Skybound Venture Capital, with participation from Protocol Labs, IAG Capital Partners and Connecticut Innovations. The funding will support the development of its minimally invasive brain‑computer interface platform...
Genesis Molecular AI Secures $120M Partnership with Incyte
Genesis Molecular AI announced a $120 million partnership with biotech giant Incyte, comprising $80 million in upfront cash and a $40 million equity investment. The collaboration will expand AI‑driven drug discovery across oncology, hematology and inflammation, with potential milestones that could push the...
Oorja Bio Secures $30M Series A Funding From Westlake
Oorja Bio, a new biotech targeting idiopathic pulmonary fibrosis, announced the closing of a $30 million Series A round on Tuesday. The round was led entirely by Westlake, providing capital to advance its drug development pipeline after the success of...
Mentari Therapeutics to Go Public via $421M Reverse Merger with InMed, Raising $290M Private Placement
Mentari Therapeutics announced a reverse merger with public shell InMed Pharmaceuticals, creating a combined company under the Mentari name with a pro forma equity value of about $421 million. The transaction includes a concurrent private placement raising roughly $290 million,...
Cellogen Therapeutics Raises $2M From Kotak Alternate Asset Managers
Biotech startup Cellogen Therapeutics secured ₹20 Cr (≈$2 M) in funding from Kotak Alternate Asset Managers via its Kotak Life Sciences Fund I. The capital will support the company’s CAR‑T clinical programmes, gene‑therapy pipeline, and GMP‑compliant manufacturing and regulatory capabilities.
Regeneron, Parabilis Set Out to Create New Drug Class in Deal Worth up to $2.3B
Regeneron has pledged $75 million to support Parabilis Medicines’ upcoming financing round and will provide up to $2.3 billion in milestone payments as part of a collaboration to develop antibody‑helicon conjugates. The partnership combines Regeneron’s ADC expertise with Parabilis’ Helicon peptide platform,...
Quince Therapeutics Acquires Orphai Therapeutics
Quince Therapeutics announced the acquisition of Orphai Therapeutics, a clinical‑stage biotech focused on rare pulmonary diseases. The deal brings Orphai’s lead inhaled rapamycin program LAM‑001 into Quince’s pipeline. The transaction was disclosed on May 18, 2026, with Cooley advising Orphai.
Avant Genomics Raises over $3M in Financing
Avant Genomics, a developer of fully‑automated liquid biopsy sample preparation for precision cancer detection, announced it has raised more than $3 million. The round was backed by TitletownTech, Halyard Ventures, Virginia Venture Partners, CAV Angels, Global Impact Fund and other angel...
Latus Bio Raises $97M Series A to Accelerate Huntington's Disease Gene Therapy
Latus Bio, a biotech startup co-founded by geneticist Beverly Davidson, announced a $97 million Series A financing in May 2026 to advance its AAV-based gene therapy platform for Huntington's disease. The round, disclosed earlier this month, will fund development of...
BioRestorative Therapies Closes $1.1M Post-Quarter Financing Round
BioRestorative Therapies Inc announced the closing of a fully‑subscribed financing round that raised approximately $1.1 million in gross proceeds. The round was priced above market and included participation from senior leadership and existing investors. The additional capital bolsters the company's cash...
Melazyme Closes $2M Seed Funding Round Led by SeaX Ventures
US‑based precision fermentation company Melazyme announced the closing of its $2 million seed round, led by SeaX Ventures with participation from Stellaris Venture Partners and Plug and Play Ventures. The funds will be used to scale up its biomolecule fermentation platform...
CREATE Medicines Raises $122M in New Funding Round
Biotech firm CREATE Medicines, formerly Myeloid Therapeutics, announced it has raised $122 million from investors Newpath Partners, ARCH Venture Partners, and Hatteras Venture Partners to advance its CAR‑T therapy pipeline. The funding will support human trials for its first CAR‑T...
Eir Partners Invests in Life Science Tech Firm QuartzBio
Eir Partners has backed QuartzBio, a provider of sample and biomarker intelligence for clinical‑stage biopharma, in a new funding round. The terms of the investment, including amount and round stage, were not disclosed.
Pfizer and Arvinas Sell Breast Cancer Drug Rights to Rigel for $35M
Pfizer and its partner Arvinas have sold the rights to their recently approved breast cancer drug to Rigel Pharmaceuticals for $35 million, a steep drop from the $1 billion invested in development.
Isomorphic Labs Closes $2.1B Series B Funding Round
Isomorphic Labs announced it has closed a $2.1 billion Series B round, the second‑largest biotech raise for a private company. The funding will accelerate its AI‑driven drug discovery platform. The round was announced on Tuesday, May 12, 2026.
Tolemy Bio Raises $1.5M Pre‑seed Round to Turn Messy Lab Data Into AI‑ready Intelligence
Cambridge‑based biotech startup Tolemy Bio announced it has closed a €1.4 million (~$1.5 million) pre‑seed round led by Norrsken Evolve, with participation from Big Sur Ventures, JME Ventures, Masia and an undisclosed UK stealth fund. The funding will support the development of its...
Aux Labs Raises $4M Seed Round Led by NYA Ventures and Nàdarra Ventures
Canadian startup Aux Labs announced a $4 million seed round led by NYA Ventures and Nàdarra Ventures to commercialize its precision‑fermentation platform for dairy proteins. The funding will support scaling using existing brewing infrastructure and further development of animal‑free cheese ingredients....
Cellular Intelligence Acquires Novo Nordisk's Parkinson's Cell Therapy
Cellular Intelligence, backed by Mark Zuckerberg, announced the acquisition of Novo Nordisk's Parkinson's disease cell therapy candidate STEM‑PD. Financial terms were undisclosed, with Novo Nordisk taking an equity stake and potential milestone payments. The deal will leverage Cellular's AI platform...
Lexicon Pharmaceuticals Secures $100M Loan Facility From Hercules Capital
Lexicon Pharmaceuticals announced a new $100 million loan facility from Hercules Capital, bolstering its balance sheet with $199.7 million in cash and investments. The financing comes as the company reports Q1 2026 revenue of $21.1 million, driven by milestones from...
Meatly Raises $13M Series A to Build Europe's Largest Lab-Grown Meat Facility
Meatly, the UK pet-food producer of cultivated meat, announced a $13 million Series A round led by Oyster Bay Venture Capital, Clean Growth Fund and JamJar Investments. The funding will finance a 20,000-litre pilot bioreactor facility in London, the largest...
Kanvas Biosciences Secures $48M Series A Funding Co-Led by DCVC and Lions Capital
Kanvas Biosciences announced a $48M Series A round co-led by DCVC and Lions Capital LLC, bringing its total funding to $78M. The capital will support clinical trials for its immuno‑oncology candidate KAN‑001 and further development of its spatial biology platform....
Scarlet Therapeutics Raises £3.2M Seed Round to Advance Lab‑grown Red Blood Cell Therapies
Scarlet Therapeutics, a UK biotech developing lab‑grown red blood cell therapies, announced a seed round of £3.2 million (≈$4.1 million) led by Eos Advisory, with participation from Oshen Bio, Daft Capital and existing backer SCVC. The funding will support pre‑clinical studies, animal...
InflaRx Raises $150M in US Public Offering to Fund Kidney Drug Development
InflaRx N.V., a Nasdaq‑listed German biotech, announced a US$150 million public offering of 75 million shares at $2.00 each to fund development of its oral C5aR inhibitor izicopan for severe renal diseases, including ANCA‑associated vasculitis. The financing attracted existing and new institutional...
Bayer to Acquire Perfuse Therapeutics in $2.45B Deal
Bayer announced it will acquire ophthalmology-focused biotech Perfuse Therapeutics, paying $300 million upfront with total consideration potentially reaching $2.45 billion based on milestones. The acquisition adds Perfuse’s PER‑001 intravitreal implant for glaucoma and diabetic retinopathy to Bayer’s pipeline. The deal, announced on...
Citius Oncology Secures $36.5M Debt and Equity Financing to Accelerate Lymphir Commercialisation
Citius Oncology announced it has secured up to $36.5 million in combined debt and equity financing to fund the commercial launch of its Lymphir immunotherapy. The financing includes a senior secured term loan of up to $25 million from Avenue...
CellCentric Secures $220M Series D Funding to Advance Multiple Myeloma Drug
CellCentric, a UK‑ and US‑based biotech, raised $220 million in a Series D round led by Venrock Healthcare Capital Partners, with participation from Pfizer, Fidelity Management & Research Company, Sofinnova Partners, RA Capital Management and Forbion. The capital will fund a Phase 3...
Biosphere Secures $9M Pentagon Grant for Portable Protein-From-Air Bioreactors
California startup Biosphere has secured a $9 million grant from the U.S. Department of Defense to develop portable UV‑sterilized bioreactors that produce protein via gas fermentation. The funding, spanning 3.5 years, will support a prototype with continuous operation, UV sterilization, water recycling...
Madrigal Outlays $1bn for Arrowhead’s siRNA MASH Asset
Madrigal Pharmaceuticals has secured global rights to Arrowhead Pharmaceuticals’ siRNA asset ARO‑PNPLA3 for the treatment of metabolic dysfunction‑associated steatohepatitis (MASH) in a licensing agreement valued at up to $1 bn, including $25 m upfront and up to $975 m in milestones. The deal...
Spyre Therapeutics Raises $463M in Underwritten Public Offering
Spyre Therapeutics announced it raised $463 million in gross proceeds from an underwritten public offering of common stock, boosting its pro‑forma cash balance to $1.2 billion. The offering, completed in April 2026, provides runway into the second half of 2029 and supports the...
Loyal Secures $100M Funding to Advance Dog Longevity Drugs
Loyal, a biotech startup developing longevity drugs for dogs, announced a $100 million fundraising round on May 5, 2026. The capital will fund further development of its IGF-1 and PPAR pathway therapies and support commercial launch plans. The round marks...
Cytospire Raises $83M Series A to Develop Pan‑gamma Delta T‑cell Engagers
Cytospire, a London‑based biotech, announced a £61 million ($83 million) Series A round led by 4BIO Capital, with participation from Abingworth, Servier Pharmaceuticals’ venture arm and other investors. The funding will advance its pan‑gamma delta T‑cell engager platform, including preclinical development of CYT X300...
Latus Bio Raises $42M to Launch Huntington’s Disease Trial
Gene therapy startup Latus Bio announced a $42 million fundraising round to fund its first clinical trials, including a gene therapy for Huntington’s disease. The capital will support the trial launch and further development of its CLN2 disease treatment. Investors were...
Moleculent Raises $20M in Funding Round Led by Rubicon Healthcare Partners
Swedish biotech Moleculent announced a $20 million fundraising round led by Rubicon Healthcare Partners, with participation from ARCH Venture Partners and Eir Ventures. The capital will be used to scale its functional profiling platform, expand into the US market, and develop...
UCB Invests $2B in Candid's T‑cell Engager Program
UCB announced a $2 billion strategic investment in Candid, a European biotech developing T‑cell engager therapies for autoimmune diseases. The funding will accelerate Candid's research and development, expanding UCB's immunotherapy pipeline. The deal was confirmed on May 4 2026.
Nuvation Bio Acquires Exclusive Rights to Safusitinib in Japan From Daiichi Sankyo
Nuvation Bio announced that it has completed the acquisition of exclusive rights to the IDH1‑mutant glioma drug safusitinib in Japan from partner Daiichi Sankyo. The agreement, finalized in April 2026, expands Nuvation’s portfolio and enables the company to advance the...
Windward Bio Raises $165M to Advance China-Derived Drug Into Phase 3 Asthma Trial
Swiss biotech startup Windward Bio announced a $165 million fundraising round to fund the development of its China-derived experimental medicines, moving a candidate into a Phase 3 asthma trial. The capital will support late-stage testing and further pipeline advancement.
UCB to Acquire Candid Therapeutics for up to $2.2 Billion
UCB announced a definitive agreement to acquire Candid Therapeutics, a clinical‑stage biotech, for up to $2.2 billion, comprising $2 billion in cash upfront and up to $200 million in milestones. The acquisition expands UCB’s T‑cell engager pipeline and is expected to close by...
LEO Pharma Signs Definitive Agreement to Acquire Gene‑therapy Company Replay for $50 Million Upfront
LEO Pharma announced it has signed a definitive agreement to acquire Replay, a gene‑therapy company that uses a herpes simplex virus vector for rare dermatological disorders. Replay’s equity holders will receive $50 million upfront plus milestone payments and royalties. The acquisition...
Valneva SE Completes €84M Reserved Offering to Fund Vaccine Pipeline
French vaccine developer Valneva SE completed an €84 million reserved offering, adding a cash buffer for its Lyme disease and shigellosis vaccine candidates. The proceeds will support R&D, commercial operations, and strengthen the balance sheet as the company navigates a high‑risk...
Chiesi Group to Acquire KalVista Pharmaceuticals for $1.9B
Chiesi Group announced a $1.9 billion cash acquisition of KalVista Pharmaceuticals, paying $27 per share, a 40.3% premium. The deal adds KalVista's oral HAE drug Ekterly to Chiesi's rare-disease portfolio and is expected to close in the third quarter of...
AbbVie to Fund Kestrel Therapeutics with up to $1.45B in Strategic Agreement, Includes Option to Acquire
Kestrel Therapeutics has signed a strategic agreement with AbbVie that provides up to $1.45 billion in funding for its pan‑KRAS inhibitor program. The deal includes an exclusive option for AbbVie to acquire Kestrel upon achievement of development and regulatory milestones.
Mbiomics Secures $32.4M Series A Funding Backed by MIG Fonds and Bayern Kapital
Mbiomics GmbH, a Munich‑based biotech startup, announced the final closing of its Series A round, raising a total of €30 million (≈$32.4 million) from existing investors MIG Fonds and Bayern Kapital. The funding will enable the company to transition from platform development to...
Teva to Acquire Emalex Biosciences for $900 Million
Teva Pharmaceutical Industries announced it will acquire Emalex Biosciences for $900 million, including a $700 million upfront payment and up to $200 million in milestones, to add the late‑stage pediatric Tourette syndrome candidate Ecopipam to its pipeline. The transaction is expected to close...
Seaport and Hemab Target $180m IPOs as Biotech Listings Accumulate
Seaport Therapeutics and Hemab Therapeutics announced Nasdaq IPO pricing, each offering roughly 11.8M and 11.7M shares at $16‑$18 per share, respectively. The companies expect net proceeds of about $183.5M and $180.3M, for a combined raise of roughly $364M, adding to...
Kailera Therapeutics Raises $718.8M in IPO, Launches on Nasdaq
Kailera Therapeutics completed its initial public offering, selling 44.9 million shares at $16 each and raising $718.8 million in gross proceeds before underwriting discounts. The shares began trading on the Nasdaq Global Select Market under ticker KLRA. The proceeds will...
Ligand Pharmaceuticals Acquires XOMA for $739 Million
Ligand Pharmaceuticals announced a $739 million acquisition of XOMA, aiming to expand its royalty revenue base and add late‑stage and commercial assets to its portfolio. The deal reflects ongoing consolidation in the biopharma sector among royalty‑financing, asset‑light companies. The transaction was...
Eli Lilly Inks $2.25B AI-Driven Enzyme Partnership with Profluent
On April 28, 2026, biotech startup Profluent and pharmaceutical giant Eli Lilly announced a multi‑program collaboration valued at up to $2.25 billion in upfront payments, milestones and royalties. The partnership focuses on AI‑designed enzymes for genetic medicines, including gene editors and...